Obstetrics and Gynecology
         HOME > Activities > Clinical Medicine > Obstetrics and Gynecology
       
       
      
      1.Research Summary
      The field of obstetrics and gynecology is classified into gynecological
      oncology, perinatology, and reproductive medicine, and highly-specialized
      research is conducted in each area. In addition, the field of reproductive
      medicine is an area related to perinatology so that research integrating
      the two is also carried out.
      2.Research Groups
      
         - Gynecological Oncology Group 
- Perinatology Group 
- Reproductive Medicine Group 
3-1.Gynecological Oncology Group
      Research subjects
      Research on the molecular biological mechanism of acquisition of taxane
      resistance in endometrial cancer
      Research on individualized treatments for ovarian cancer based on analyses
      of gene expression profiles and proteomes
      Research on identification of causative genes of ovarian cancer by genome-wide
      exome analysis
      Research on identification of causative genes of familial ovarian cancer
      Research on searching for lymph node micrometastasis during sentinel lymph-node
      navigation surgery in cervical cancer
      Research on clarification of molecular mechanisms of the onset and progression
      of endometrial cancer targeting adipocytokines
      Research on identification of genes susceptible to endometriosis
      Research on adjuvant chemotherapy for high-risk endometrial cancer (Echigo
      Gynecological Oncology Study Group) 
      Current clinical research participation
      Ovarian cancer
    
         - A Phase III, randomized, controlled study on the necessity of adjuvant
         chemotherapy in patients with stage I epithelial ovarian cancer who underwent
         staging surgery (JG0G3020) 
- A Phase II/III, randomized study of paclitaxel administered weekly as an
         intravenous infusion + carboplatin administered every 3 weeks as an intravenous
         infusion vs. paclitaxel administered weekly as an intravenous infusion
         + carboplatin administered every 3 weeks as an intraperitoneal infusion
         in patients with epithelial ovarian cancer, fallopian tube cancer or primary
         peritoneal cancer (JGOG3019) 
- A Phase III, randomized, controlled study of pegylated liposomal doxorubicin
         (PLD) 50 mg/㎡ vs. PLD 40 mg/㎡ in patients with platinum-resistant recurrent
         or relapsed Mullerian carcinoma (epithelial ovarian cancer, primary fallopian
         tube cancer or peritoneal cancer) (JGOG3018) 
- A Phase III, randomized, controlled study to evaluate the efficacy of secondary
         cytoreductive surgery and the efficacy of bevacizumab used as maintenance
         therapy in combination with carboplatin + paclitaxel therapy in patients
         with platinum-sensitive recurrent ovarian cancer, primary peritoneal cancer
         or fallopian tube cancer (GOG0213) 
- A Phase II study of temsirolimus maintenance therapy following temsirolimus
         + carboplatin + paclitaxel therapy as a first-line treatment in patients
         with stage III-IV ovarian clear cell adenocarcinoma (GOG0268) 
Cervical cancer
      
         - A Phase III, randomized study of postoperative radiotherapy and concurrent
         chemoradiotherapy in patients with intermediate-risk, stage I/IIa cervical
         cancer who underwent extended hysterectomy and pelvic lymphadenectomy as
         the initial treatment (GOG0263) 
Endometrial cancer
     
         - A Phase II, randomized study of TEC (Paclitaxel + Epirubicin + Carboplatin)
         therapy, TAC (Paclitaxel + Doxorubicin + Carboplatin) therapy, and ddTC
         (Dose-dense Paclitaxel + Carboplatin) therapy as postoperative chemotherapy
         in groups at intermediate and high risk for postoperative recurrent endometrial
         cancer (GOGO-EM3/Intergroup Study) 
Other
      
         - Comparative analysis of CA-IX, p16, proliferation markers and human papillomavirus
         (HPV) in diagnosis of cervical lesions in patients with a cytodiagnosis
         of atypical glandular cells (AGCs) (GOG0237) 
3-2.Perinatology Group
      Research subjects
      Research on immunological abnormalities and prevention in abnormal pregnancy
      Research on prevention of fetal arrhythmias from the autoimmune perspective
      Research on the systemization of fetal abnormality detection by ultrasound
      tomography
      3-3.Reproductive Medicine Group
      Research subjects
      Research on treatment of habitual abortion due to alloimmune abnormality
      and repeated in vitro fertilization-embryo transfer failure
      Research on gene polymorphisms of detoxification enzymes for habitual abortion
      of unknown cause
      Research on habitual abortion due to autoimmune abnormality and repeated
      in vitro fertilization-embryo transfer failure
      Research on assisted reproduction technologies for the prevention of secondary
      infection in HIV-positive married couples
      Research on the relationship between habitual abortion and cytokine gene
      polymorphisms 
      4.Research Results
      
         
            | [Area] Gynecological Oncology Group | 
            | [Research subject] Research on individualized treatment of ovarian cancer
            based on gene expression profiles | 
            | [Description]Serous ovarian cancer is the most frequent tissue type of epithelial ovarian
            cancer. Its 5-year survival rate is around 40%, and new therapeutic strategies
            for improving prognosis have been awaited. In recent years, ovarian cancer,
            from a molecular biological standpoint, is considered to be a heterogeneous
            disease. This research focused on this molecular biological heterogeneity
            to establish a prognostic system for predicting advanced serous ovarian
            cancer based on gene expression profiles for improving prognosis by individualized
            treatment.
 An elastic net analysis with 10-fold cross validation was performed using
            gene expression data from 260 patients with advanced serous ovarian cancer,
            and a prognostic index composed of 126 genes was developed. Based on the
            prognostic index, high and low risks were determined, and the predictive
            performance of these classifications was checked with validation data (816
            patients). Furthermore, changes in the immune system, particularly antigen
            presentation pathways in cancer cells, were identified as being strongly
            inhibited in the high risk group.
 Currently, we are performing research to clinically apply genetic testing
            in the high risk group, promote enhancement of the antitumor effect of
            host immune cells by the reactivation of antigen presentation pathways,
            and improve the prognosis of the high risk group.
 (Yoshihara K & Tajima A, et al. Cancer Sci 2009; Yoshihara K, et al.
            PLoS ONE 2010; Yoshihara K, et al.: Clin Cancer Res, 18:1374-85, 2012.)
 | [Photographs] 
 | 
            |  |  | 
      
      
         
            | [Area] Reproductive Medicine Group | 
            | [Research subject] Research on gene polymorphisms of detoxification enzymes
            for habitual abortion of unknown cause | 
            | [Description]In recent years, the involvement of detoxification genetic factors has
            been suggested to be a cause of habitual abortion. Toxic substances contained
            in favorite foods are activated by CYP1A1 and detoxified by GSTs. Decreased
            activation of detoxification enzymes during pregnancy delays the elimination
            of toxic substances from the body, and abortion may occur. However, the
            cause has not been fully elucidated such that this research aimed to reveal
            this aspect. A questionnaire survey on favorite foods was carried out in
            96 patients who had habitual abortions (at least 3 abortions early in pregnancy)
            (patient group). A gene polymorphism analysis was conducted using genomic
            DNA to determine the gene polymorphisms of each enzyme including CYP1A1,
            GST-π, GST-μ, and GST-θ by the PCR-RFLP method. A total of 96 women who
            had experienced childbirth at least twice and had no history of abortion
            were included in the control group. There were no significant differences
            in gene frequencies between the two groups for CYP1A1, GST-π, GST-μ, or
            GST-θ. Favorite foods and gene frequencies were compared between the two
            groups. The results showed GST-μ deletions in 41 of 67 patients (61%) in
            the patient group and 28 (41%) of 68 patients in the control group in relation
            to coffee drinking; the rate was significantly higher in the patient group
            (chi-square test). The above results suggested that coffee drinking might
            be associated with the onset of habitual abortion in women with deletion
            of GST-μ among the detoxification factors, and this could be used for lifestyle
            habit guidance for the prevention of habitual abortion.
 (Nonaka T, Takakuwa K, et al.Journal of Obstetrics and Gynaecology Research,
            37:1352-1358, 2011.)
 | [Photographs] 
 | 
            |  |  | 
      
      
         
            | [Area] Reproductive Medicine Group | 
            | [Research subject] Research on in vitro fertilization-embryo transfer in
            married HIV-positive men | 
            | [Description]With the improvement of treatment drugs, HIV-infected patients can live
            for a long time and may wish to get married and have children. When 100
            married couples consisting of HIV-positive men and HIV-negative women attempted
            to get pregnant by usual intercourse, 4.8 women/year were reported to be
            infected with HIV, and secondary infection of women by artificial insemination
            has also been reported. From this standpoint, it is important to establish
            safe assisted reproduction technologies without the risk of secondary infection
            for married couples consisting of HIV-positive men and HIV-negative women.
            In our department, we have been performing in vitro fertilization-embryo
            transfer using the modified swim-up technique and RT-nested PCR method
            as safer assisted reproduction technologies for married couples consisting
            of HIV-positive men and HIV-negative women since 2001. We have implemented
            this therapy in 58 such married couples so far. The women underwent 102
            cycles of ovulation induction, and pregnancy was achieved following 29
            fresh embryo transfer cycles (42.0%) and 8 frozen embryo transfer cycles
            (25.8%). A total of 28 married couples (48.3%), excluding women with abortions,
            who underwent this therapy, delivered children. In addition, no secondary
            infections were noted in any of the wives who underwent embryo transfers
            or their babies born after this procedure. Based on the above, this therapy
            has been determined to be effective and safe.
 (Kato S, Takakuwa K, et al. AIDS, 20:967-73, 2006. Kashima K, Takakuwa
            K, et al. Japanese Journal of Infectious Disease. 62: 173-176, 2009.)
 | [Photographs] 
 | 
            |  |  | 
      
Please see the Obstetrics and Gynecology website for a detailed description of our research.